Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On January 9, 2023, Xtant Medical Holdings, Inc. (the "Company") announced the
appointment of Mark A. Schallenberger as Chief Operations Officer, effective as
of January 16, 2023.
Mr. Schallenberger, age 37, has deep experience in orthobiologics. Prior to
joining Xtant Medical, Mr. Schallenberger served as Chief Operations Officer of
Surgenex LLC, a medical technology manufacturer, from June 2019 to January 2023.
Prior to Surgenex, Mr. Schallenberger served as Senior Director of Marketing &
Product Development of DCI Donor Services Tissue Bank, a tissue bank, from
February 2016 to June 2019. Prior to DCI Donor Services Tissue Bank, Mr.
Schallenberger served in various roles with increasing responsibility from
September 2010 to February 2016 culminating with Director of Scientific Affairs
with Xtant Medical Holdings, Inc. formerly Bacterin International Holdings, Inc.
Mr. Schallenberger holds a Master of Science in Chemical Biology from The
Scripps Research Institute and a Bachelor of Science degree in Chemistry from
the University of Montana.
In connection with his appointment as an executive officer of the Company, Mr.
Schallenberger and the Company entered into an employment agreement, offer
letter agreement, and indemnification agreement. Under the terms of the
employment agreement, Mr. Schallenberger will serve as Chief Operations Officer,
effective as of January 16, 2023, and in consideration thereof, will receive an
annual base salary of $400,000, a potential annual bonus of 50% of base salary,
and will be granted an option to purchase 105,000 shares of the Company's common
stock and a restricted stock unit award covering 89,000 shares of the Company's
common stock under the Xtant Medical Holdings, Inc. Second Amended and Restated
2018 Equity Incentive Plan (the "Plan"), effective as of February 15, 2023,
which is the 15th day of the month after his first date of employment,
consistent with the Company's equity grant policy. The options will have a
10-year term and a per share exercise price equal to the "fair market value" (as
defined in the Plan) of the Company's common stock on the grant date. The
options will vest with respect to 25% of the shares of common stock purchasable
thereunder on the one-year anniversary of the grant date and quarterly
thereafter and the restricted stock units will vest in four equal annual
installments, in each case conditioned upon Mr. Schallenberger's continued
employment with the Company and/or its subsidiaries from the grant date until
the respective vesting date. The employment agreement contains severance
provisions which provide that in the event Mr. Schallenberger's employment is
terminated by the Company without "cause" (as defined in the agreement) after
July 16, 2023, he will be entitled to receive a severance payment equal to 12
months base salary payable as salary continuation payments, a prorated bonus for
the year of termination if earned pursuant to the terms of the bonus plan, and
reimbursement of COBRA payments for 12 months, and in the event his employment
is terminated by the Company after July 16, 2023 and within 12 months following
a "change in control" or should he resign for "good reason" (as such terms are
defined in the agreement) within that period, then his 12 months base salary
will be paid to him in a lump-sum payment. To be eligible to receive these
payments, Mr. Schallenberger will be required to execute and not revoke a
release of claims. The agreement also contains standard confidentiality,
non-competition, non-solicitation and assignment of intellectual property
provisions.
Under the term of the offer letter agreement, Mr. Schallenberger was offered the
position of Chief Operations Officer on substantially the terms as described
above. Once effective, the employment agreement will supersede and replace the
offer letter agreement.
The indemnification agreement with Mr. Schallenberger is substantially similar
to the indemnification agreements between the Company and its executive officers
and may require the Company, among other things, to indemnify Mr. Schallenberger
for costs associated with any fees, expenses, judgments, fines and settlement
amounts incurred by him or on his behalf in any action or proceeding to which he
is, or is threatened to be, made a party by reason of his service as an officer,
including any action by the Company, arising out of his service as an officer or
his services provided to any other company or enterprise at the Company's
request.
The foregoing summary description of the employment agreement, option award,
restricted stock unit award, offer letter agreement and indemnification
agreement with Mr. Schallenberger does not purport to be complete and is
qualified in its entirety by reference to the full text of the employment
agreement, form of option award agreement, form of restricted stock unit award
agreement, offer letter agreement, and form of indemnification agreement, which
are filed as Exhibits 10.1, 10.2, 10.3, 10.4 and 10.5, respectively, to this
Current Report on Form 8-K and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On January 9, 2023, the Company issued a press release announcing the officer
appointment described above, which is attached as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated herein by reference.
The information in Item 7.01 of this report (including Exhibit 99.1) shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly provided by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
10.1 Employment Agreement dated as of January 16, 2023 between Xtant
Medical Holdings, Inc. and Mark A. Schallenberger (filed herewith)
10.2 Form of Employee Stock Option Award Agreement for use with the
Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan
(incorporated by reference to Exhibit 10.2 to the Company's Current
Report on Form 8-K filed with the Securities and Exchange Commission
on August 3, 2018 (SEC File No. 001-34951))
10.3 Form of Employee Restricted Stock Unit Award Agreement for use
with the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan
(incorporated by reference to Exhibit 10.3 to the Company's Current
Report on Form 8-K filed with the Securities and Exchange Commission
on August 3, 2018 (SEC File No. 001-34951))
10.4 Offer Letter Agreement dated as of December 14, 2022 between Xtant
Medical Holdings, Inc. and Mark A. Schallenberger (filed herewith)
10.5 Form of Indemnification Agreement for Directors and Officers
(incorporated by reference to Exhibit 10.6 to the Company's
Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2017 (SEC File No. 001-34951))
99.1 Press Release dated January 9, 2023 (furnished herewith)
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses